foxo4-dri senolytic human trial 2024 2025 The costs and benefits of senotherapeutics for health What are the recommended dosing
What are the recommended dosing regimens, safety monitoring, and clinical trial considerations for senolytic agents such as dasatinib + quercetin, navitoclax, fisetin, and FOXO4DRI? Rubedo Life Sciences has reached an exciting milestone with the launch of its Phase 1 clinical trial for RLS1496, a firstinclass GPX4 modulator designed to selectively target pathologic senescent cells, a key FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS
Pay in 4 interest-free payments of $6.64 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10

